The worldwide surge of SARS-CoV-2 started during the first week of the study. The Investigators attempted to re-organize the project with a new agenda, but the time frame from the funding Organization did not comply with the study needs.
PSP
Sponsor study identifier
observational
9
1 country
1
Study Start
February 12, 2020
Actual (reported)Primary Completion
October 30, 2020
Actual (reported)Study Completion
October 30, 2020
Actual (reported)This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national). Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam. The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods. Secondary objectives:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 30, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 12, 2020
Actual (reported)February 20, 2020
Actual (reported)February 25, 2020
Actual (reported)October 30, 2020
Actual (reported)October 30, 2020
Actual (reported)Adherence
Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
12 months
Organization model
18 months
Smoking cessation
24 months
Secondary prevention of lung cancer
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program. Inclusion criteria * Age between 50 and 75 years * Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years * Status of current smoker or ex-smoker for \<10 years. Exclusion criteria • Personal history of cancer within the prior 5 years
Early detection of lung cancer by LDCT and smoking cessation counselling
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
University of Parma
Parma, Italy
Nicola Sverzellati, MD, PhD
University of Parma
9 participants (actual enrollment reported by the registry).
First Submitted
February 20, 2020
First Posted
February 25, 2020
Study Start
February 12, 2020
Actual (reported)24 mesi
Work up burden
24 months
False positives
24 months
Contact the study team to confirm eligibility.
Primary Completion
October 30, 2020
Actual (reported)Study Completion
October 30, 2020
Actual (reported)Last Updated
November 19, 2021
Record last verified: 2020-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: